Efficacy of Azithromycin for Treating Babesia microti Infection in the Hamster Model

Louis M. Weiss(Albert Einstein College of Medicine), Herbert B. Tanowitz(Albert Einstein College of Medicine), Helieh S. Oz(Pfizer (United States)), Murray Wittner(Pfizer (United States)), Scott M. Wasserman(Amgen (United States)), James A. Retsema(Pfizer (United States))
The Journal of Infectious Diseases
November 1, 1993
10.1093/infdis/168.5.1289
Cited by 48

Related Papers

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
|JAMA|2016|1.1k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712